Structural insights into the enzymes of the trypanothione pathway: Targets for antileishmaniasis drugs

Future Medicinal Chemistry

Volumn 5, Issue 15, 2013, Pages 1861-1875

  Colotti, Gianni ^a,b   Baiocco, Paola ^b   Fiorillo, Annarita ^b   Boffi, Alberto ^b   Poser, Elena ^b   Chiaro, Francesco Di ^b   Ilari, Andrea ^a,b  

^a CNR   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIPHENAZOLE; ANTIPROTOZOAL AGENT; AUROTHIOGLUCOSE; AUROTHIOMALATE; BETULIN; GLUTATHIONE DERIVATIVE; GLUTATHIONE SYNTHASE; GOLD COMPLEX; GOLD DERIVATIVE; INDAZOLE DERIVATIVE; MEPACRINE; N BENZOYLOXYCARBONYL (2,4DINITROPHENYL)GLUTATHIONE ESTER; PAULLONE DERIVATIVE; PEROXIDASE; PHENYLPYRAZOLE; PHOSPHINIC ACID DERIVATIVE; PLATINUM COMPLEX; PROCHLORPERAZINE; PROTOZOAL PROTEIN; PYRAZOLE DERIVATIVE; SILVER DERIVATIVE; SPERMIDINE SYNTHASE; TOMATINE; TRIPHENYLTETRAZOLIUM; TRYPANOTHIONE; TRYPANOTHIONE REDUCTASE; TRYPANOTHIONE SYNTHETASE AMIDASE; TRYPAREDOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVAOL;

BINDING SITE; DISULFIDE BOND; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; ENZYME BINDING; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; ENZYME SYNTHESIS; HUMAN; LEISHMANIA; LEISHMANIASIS; NONHUMAN; PARASITE SURVIVAL; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ANALYSIS;

AMIDE SYNTHASES; ANTIPROTOZOAL AGENTS; BINDING SITES; CATALYTIC DOMAIN; GLUTATHIONE; GOLD; HUMANS; LEISHMANIA; MOLECULAR DOCKING SIMULATION; NADH, NADPH OXIDOREDUCTASES; PROTOZOAN PROTEINS; SILVER; SPERMIDINE;

EID: 84886497242     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.146     Document Type: Review

References (82)

1. Simpson AG, Stevens JR, Lukes J. The evolution and diversity of kinetoplastid flagellates. Trends Parasitol. 22(4), 168-174 (2006
2. The WHO. Education is key to controlling visceral leishmaniasis. Bull. World Health Organ. 88(1), 11-12 (2010
3. BenSaid M, Guerbouj S, Saghrouni F, Fathallah-Mili A, Guizani I. Occurrence of Leishmania infantum cutaneous leishmaniasis in central Tunisia. Trans. R. Soc. Trop. Med. Hyg. 100(6), 521-526 (2006
4. Lukes J, Mauricio IL, Schonian G. et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc. Natl Acad. Sci. USA 104(22), 9375-9380 (2007
5. Dujardin JC, Campino L, Canavate C et al. Spread of vector-borne diseases and neglect of Leishmaniasis, Europe. Emerg. Infect. Dis. 14(7), 1013-1018 (2008
6. Christodoulou V, Antoniou M, Ntais P et al. Re-emergence of visceral and cutaneous leishmaniasis in the Greek Island of Crete. Vector Borne Zoonotic Dis. 12(3), 214-222 (2012
7. Fischer D, Moeller P, Thomas SM, Naucke TJ, Beierkuhnlein C. Combining climatic projections and dispersal ability: A method for estimating the responses of sandfly vector species to climate change. PLoS Negl. Trop. Dis. 5(11), e1407 (2011
8. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg. 95, 239-243 (2001
9. Fyfe PK, Westrop GD, Silva AM, Coombs GH, Hunter WN. Leishmania TDR1 structure, a unique trimeric glutathione transferase capable of deglutathionylation and antimonial prodrug activation. Proc. Natl Acad. Sci. USA 109(29), 11693-11698 (2012
10. Lira R, Sundar S, Makharia A et al. Evidence that the high incidence of treatment failures in Indian kala-Azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180(2), 564-567 (1999
11. Hadighi R, Mohebali M, Boucher P et al. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 3(5), e162 (2006
12. Sundar S, Pai K, Kumar R et al. Resistance to treatment in Kala-Azar: Speciation of isolates from northeast India. Am. J. Trop. Med. Hyg. 65(3), 193-196 (2001
13. Abdo MG, Elamin WM, Khalil EA, Mukhtar MM. Antimony-resistant Leishmania donovaniin eastern Sudan: Incidence and in vitro correlation. East Mediterr. Health J. 9(4), 837-843 (2003
14. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8, 319-342 (2002
15. Shakya N, Bajpai P, Gupta S. Therapeutic switching in leishmania chemotherapy: A distinct approach towards unsatisfied treatment needs. J. Parasit. Dis. 35(2), 104-112 (2011
16. Davidson RN, Croft SL, Scott A et al. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 337(8749), 1061-1062 (1991
17. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19(1), 111-126 (2006
18. El-Sayed NM, Myler PJ, Blandin G et al. Comparative genomics oftrypanosomatid parasitic protozoa. Science 309(5733), 404-409 (2005
19. Colotti G, Ilari A. Polyamine metabolism in Leishmania: From arginine to trypanothione. Amino Acids 40(2), 269-285 (2011
20. Krauth-Siegel RL, Comini MA. Redox control in trypanosomatids parasitic protozoa with trypanothione-based thiol metabolism. Biochim. Biophys. Acta 1780(11), 1236-1248 (2008
21. Fairlamb AH, Blackburn P, Ulrich P, Chait BT, Cerami A. Trypanothione: A novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science 227(4693), 1485-1487 (1985
22. Freason JA, Wyatt PG, Gilbert IH, Fairlamb AH. Target assessment for antiparasitic drug discovery. Trends Parasitol. 23, 589-595 (2007
23. Dumas C, Ouellette M, Tovar J et al. Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J. 16(10), 2590-2598 (1997
24. Romao S, Castro H, Sousa C, Carvalho S, Tomas AM. The cytosolic tryparedoxin of Leishmania infantum is essential for parasite survival. Int. J. Parasitol. 39, 703-711 (2009
25. Barr SD, Gedamu L. Role of peroxidoxins in Leishmania chagasi survival. Evidence of an enzymatic defense against nitrosative stress. J. Biol. Chem. 278, 10816-10823 (2003
26. Comini MA, Krauth-Siegel RL, Flohe L. Depletion of the thioredoxin homologue tryparedoxin impairs antioxidative defence in African trypanosomes. Biochem. J. 402, 43-49 (2007
27. Wilkinson SR, Kelly JM. The role of glutathione peroxidases in trypanosomatids. Biol. Chem. 384, 517-525 (2003
28. Flohè L. The trypanothione system and the opportunities it offers to create drugs for the neglected kinetoplast diseases. Biotechnol. Adv. 30, 294-301 (2011
29. Eberle C, Burkhard JA, Stump B et al. Synthesis, inhibition potency, binding mode, and antiprotozoal activities of f luorescent inhibitors of trypanothione reductase based on mepacrine-conjugated diaryl sulfide scaffolds. ChemMedChem 4, 2034-2044 (2009
30. Eberle C, Lauber BS, Fankhauser D et al. Improved inhibitors of trypanothione reductase by combination of motifs: Synthesis, inhibitory potency, binding mode, and antiprotozoal activities. ChemMedChem 6, 292-301 (2011
31. Meiering S, Inhoff O, Mies J et al. Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis. J. Med. Chem. 48, 4793-4802 (2005
32. Spinks D, Shanks EJ, Cleghorn LA et al. Investigation of trypanothione reductase as a drug target in Trypanosoma brucei. ChemMedChem 4, 2060-2069 (2009
33. Krieger S, Schwarz W, Ariyanayagam MR, Fairlamb AH, Krauth-Siegel RL, Clayton C. Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Mol. Microbiol. 35(3), 542-552 (2000
34. Wyllie S, Oza SL, Patterson S et al. Dissecting the essentiality of the bifunctional trypanothione synthetase-Amidase in Trypanosoma brucei using chemical and genetic methods. Mol. Microbiol. 74(3), 529-540 (2009
35. Baiocco P, Poce G, Alfonso S et al. Inhibition of leishmania infantum trypanothione reductase by azole-based compounds: A comparative analysis with its physiological substrate by x-ray crystallography. ChemMedChem 8, 1175-1183 (2013
36. Fyfe PK, Oza SL, Fairlamb AH, Hunter WN. Leishmania trypanothione synthetase-Amidase structure reveals a basis for regulation of conflicting synthetic and hydrolytic activities. J. Biol. Chem. 283(25), 17672-17680 (2008
37. Pai CH, Chiang BY, Ko TP et al. Dual binding sites for translocation catalysis by Escherichia coli glutathionylspermidine synthetase. EMBO J. 25(24), 5970-5982 (2006
38. Murzin AG. Structural classification of proteins: New superfamilies. Curr. Opin. Struct. Biol. 6(3), 386-394 (1996
39. Polekhina G, Board PG, Gali RR, Rossjohn J, Parker MW. Molecular basis of glutathione synthetase deficiency and a rare gene permutation event. EMBO J. 18(12), 3204-3213 (1999
40. Koch O, Cappel D, Nocker M et al.Molecular dynamics reveal binding mode of glutathionylspermidine by trypanothione synthetase. PLoS ONE 8(2), e56788 (2013
41. Daunes S, D'Silva C, Kendrick H, Yardley V, Croft SL. QSAR study on the contribution of log P and E(s) to the in vitro antiprotozoal activity of glutathione derivatives. J. Med. Chem. 44, 2976-2983 (2001
42. Kunick C, Lauenroth K, Leost M, Meijer L, Lemcke T. 1-Azakenpaullone is a selectiveinhibitor of glycogen synthase kinase-3 beta. Bioorg. Med. Chem. Lett. 14, 413-416 (2004
43. Oza SL, Chen S, Wyllie S, Coward JK, Fairlamb AH. ATP-dependent ligases in trypanothione biosynthesis-kinetics of catalysis and inhibition by phosphinic acid pseudopeptides. FEBS J. 275(21), 5408-5421 (2008
44. Torrie LS, Wyllie S, Spinks D et al. Chemical validation of trypanothione synthetase, a potential drug target for human trypanosomiasis. J. Biol. Chem. 284, 36137-36145 (2009
45. Spinks D, Torrie LS, Thompson S et al. Design, synthesis and biological evaluation of Trypanosoma brucei trypanothione synthetase inhibitors. ChemMedChem 7(1), 95-106 (2012
46. Saudagar P, Dubey VK. Cloning, expression, characterization and inhibition studies on trypanothione synthetase, a drug target enzyme, from Leishmania donovani. Biol. Chem. 392, 1113-1122 (2011
47. Baiocco P, Franceschini S, Ilari A, Colotti G. Trypanothione reductase from Leishmania infantum: Cloning, expression, purification, crystallization and preliminary x-ray data analysis. Protein Pept. Lett. 16(2), 196-200 (2009
48. Baiocco P, Colotti G, Franceschini S, Ilari A. Molecular basis of antimony treatment in leishmaniasis. J. Med. Chem. 52(8), 2603-2612 (2009
49. Reynolds C, Damerell D, Jones S. ProtorP: A protein-protein interaction analysis server. Bioinformatics 25(3), 413-414 (2009
50. Karplus PA, Schulz GE. Substrate binding and catalysis by glutathione reductase as derived from refined enzyme: Substrate crystal structures at 2 Å resolution. J. Mol. Biol. 210(1), 163-180 (1989
51. Krauth-Siegel RL, Arscott LD, Schonleben-Janas A, Schirmer RH, Williams CH Jr. Role of active site tyrosine residues in catalysis by human glutathione reductase. Biochemistry 37(40), 13968-13977 (1998
52. Berkholz DS, Faber HR, Savvides SN, Karplus PA. Catalytic cycle of human glutathione reductase near 1 Å resolution. J. Mol. Biol. 382(2), 371-384 (2008
53. O'Sullivan MC. The battle against trypanosomiasis and leishmaniasis: Metal based and natural product inhibitors of trypanothione reductase. Curr. Med. Chem. Anti-Infect. Agents 4(4), 355-378 (2005
54. Lowe G, Droz AS, Vilaivan T et al. Cytotoxicity of (2,2́:6́, 2́́-Terpyridine) platinum(II) complexes to Leishmania donovani, Trypanosoma cruzi, and Trypanosoma brucei. J. Med. Chem. 42(6), 999-1006 (1999
55. Bonse S, Richards JM, Ross SA, Lowe G, Krauth-Siegel RL. (2,2́:6́,2́́-Terpyridine) platinum(II) complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase. J. Med. Chem. 43(25), 4812-4821 (2000
56. Navarro M, Hernandez C, Colmenares I et al. Synthesis and characterization of [Au(dppz)2]Cl3. DNA interaction studies and biological activity against Leishmania (L) mexicana. J. Inorg. Biochem. 101(1), 111-116 (2007
57. Vieites M, Smircich P, Guggeri L et al. Synthesis and characterization of a pyridine-2-Thiol N-oxide gold(I) complex with potent antiproliferative effect against Trypanosoma cruzi and Leishmania sp. insight into its mechanism of action. J. Inorg. Biochem. 103(10), 1300-1306 (2009
58. Ilari A, Baiocco P, Messori L et al. A gold-containing drug against parasitic polyamine metabolism: The x-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition. Amino Acids 42(2-3), 803-811 (2012
59. Kean WF, Kean IR. Clinical pharmacology of gold. Inflammopharmacology 16(3), 112-125 (2008
60. Liau SY, Read DC, Pugh WJ, Furr JR, Russell AD. Interaction of silver nitrate with readily identifiable groups: Relationship to the antibacterial action of silver ions. Lett. Appl. Microbiol. 25(4), 279-283 (1997
61. Baiocco P. Ilari A, Ceci P et al. Inhibitory effect of silver nanoparticles on trypanothione reductase activity and Leishmania infantum proliferation. ACS Med. Chem. Lett. 2, 230-233 (2011
62. Pujals G, Sune-Negre JM, Perez P et al. In vitro evaluation of the effectiveness and cytotoxicity of meglumine antimoniate microspheres produced by spray drying against Leishmania infantum. Parasitol. Res. 102(6), 1243-1247 (2008
63. Jacoby EM, Schlichting I, Lantwin CB, Kabsch W, Krauth-Siegel RL. Crystal structure of the Trypanosoma cruzi trypanothione reductase mepacrine complex. Proteins 24(1), 73-80 (1996
64. Saravanamuthu A, Vickers TJ, Bond CS, Peterson MR, Hunter WN, Fairlamb AH. Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: A template for drug design. J. Biol. Chem. 279(28), 29493-29500 (2004
65. Garforth J, Yin H, McKie JH, Douglas KT, Fairlamb AH. Rational design of selective ligands for trypanothione reductase from Trypanosoma cruzi. Structural effects on the inhibition by dibenzazepines based on imipramine. J. Enzyme Inhib. 12(3), 161-173 (1997
66. Bonse S, Santelli-Rouvier C, Barbe J, Krauth-Siege, RL. Inhibition of Trypanosoma cruzi trypanothione reductase by acridines: Kinetic studies and structure-Activity relationships. J. Med. Chem. 42(26), 5448-5454 (1999
67. Salmon-Chemin L, Buisine E, Yardley V et al. 2-And 3-substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: Synthesis and correlation between redox cycling activities and in vitro cytotoxicity. J. Med. Chem. 44(4), 548-565 (2001
68. McKie JH, Garforth J, Jaouhari R et al. Specific peptide inhibitors of trypanothione reductase with backbone structures unrelated to that of substrate: Potential rational drug design lead frameworks. Amino Acids 20(2), 145-153 (2001
69. Stump B, Eberle C, Kaiser M et al. Diaryl sulfide-based inhibitors of trypanothione reductase: Inhibition potency, revised binding mode and antiprotozoal activities. Org. Biomol. Chem. 6(21), 3935-3947 (2008
70. Patterson S, Alphey MS, Jones DC et al. Dihydroquinazolines as a novel class of Trypanosoma brucei trypanothione reductase inhibitors: Discovery, synthesis, and characterization of their binding mode by protein crystallography. J. Med. Chem. 54(19), 6514-6530 (2011
71. Wood ZA, Poole LB, Karplus PA. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 300(5619), 650-653 (2003
72. Olin-Sandoval V, Moreno-Sanchez R, Saavedra E. Targeting trypanothione metabolism in trypanosomatid human parasites. Curr. Drug Targets 11(12), 1614-1630 (2010
73. Flohe L. The trypanothione system and the opportunities it offers to create drugs for the neglected kinetoplast diseases. Biotechnol. Adv. 30(1), 294-301 (2012
74. Alphey MS, Bond CS, Tetaud E, Fairlamb AH, Hunter WN. The structure of reduced tryparedoxin peroxidase reveals a decamer and insight into reactivity of 2Cys-peroxiredoxins. J. Mol. Biol. 300(4), 903-916 (2000
75. Alphey MS, Konig J, Fairlamb AH. Structural and mechanistic insights into type II trypanosomatid tryparedoxin-dependent peroxidases. Biochem J. 414(3), 375-381 (2008
76. Cao Z, Tavender TJ, Roszak AW, Cogdell RJ, Bulleid NJ Crystal structure of reduced and of oxidized peroxiredoxin IV enzyme reveals a stable oxidized decamer and a non-disulfide-bonded intermediate in the catalytic cycle. J. Biol. Chem. 286(49), 42257-42266 (2011
77. Fiorillo A, Colotti G, Boffi A, Baiocco P, Ilari A. The crystal structures of the tryparedoxin-Tryparedoxin peroxidase couple unveil the structural determinants of Leishmania detoxification pathway. PLoS Negl. Trop. Dis. 6(8), e1781 (2012
78. Wang X, Wang L, Sun F, Wang CC. Structural insights into the peroxidase activity and inactivation of human peroxiredoxin 4. Biochem. J. 441(1), 113-118 (2012
79. Budde H, Flohe L, Hecht HJ et al. Kinetics and redox-sensitive oligomerisation reveal negative subunit cooperativity in tryparedoxin peroxidase of Trypanosoma brucei brucei. Biol. Chem. 384(4), 619-633 (2003
80. Comini MA, Flohé L.Trypanothione-based redox metabolism of trypanosomatids. In: Trypanosomatid Diseases. Jäger T, Koch O, Flohé L (Eds). Wiley-Blackwell, Weinheim, Germany, 167-199 (2013
81. Beig M, Oellien F, Krauth-Siegel RL, Selzer PM. Screening approaches towards trypanothione reductase. In: Trypanosomatid Diseases. Jäger T, Koch O, Flohé L (Eds). Wiley-Blackwell, Weinheim, Germany, 385-404 (2013
82. Lee B, Bauer H, Melchers J et al. Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: A divinyl ketone as key intermediate. J. Med. Chem. 48, 7400-7410 (2005)